Literature DB >> 27783167

Clinicopathological features of Siewert type II adenocarcinoma: comparison of gastric cardia adenocarcinoma and Barrett's esophageal adenocarcinoma following endoscopic submucosal dissection.

Hiroki Osumi1, Junko Fujisaki2, Masami Omae1, Tomoki Shimizu1, Toshiyuki Yoshio1, Akiyoshi Ishiyama1, Toshiaki Hirasawa1, Tomohiro Tsuchida1, Yorimasa Yamamoto1, Hiroshi Kawachi3, Noriko Yamamoto3, Masahiro Igarashi1.   

Abstract

OBJECTIVES: Siewert type II esophagogastric junction adenocarcinoma encompasses both gastric cardia adenocarcinoma (GCA) and Barrett's esophageal adenocarcinoma (BEA) due to short-segment Barrett's esophagus. We compared these two types of Siewert type II esophagogastric junction adenocarcinoma in terms of background factors and clinical outcomes of endoscopic submucosal dissection (ESD).
METHODS: We enrolled 139 patients (142 lesions) who underwent ESD from 2006 to 2014 at our institution. Background factors evaluated were age, sex, body mass index, hypertension, hyperlipidemia, hyperuricemia, diabetes mellitus, smoking, drinking, double cancer, and endoscopic findings. Clinical outcomes evaluated were procedure time, en bloc resection rate, curative resection rate, and adverse events.
RESULTS: There were 87 GCA lesions (61.2%) and 55 BEA lesions. Features of BEA [55 lesions (38.8%)] included a younger age, small diameter, and a protruding type, along with a high frequency of esophageal hiatal hernia and less mucosal atrophy. There were no significant differences in lifestyle-related background factors between the GCA and BEA groups. Curative resection rate was greater for GCA (81%) than for BEA (66%) (P = 0.01). There were no serious adverse events in either group. Among the factors for noncurative resection, lymphovascular invasion and depth of invasion were greater for BEA (33.3 vs. 7 and 20.7 vs. 8.2%, respectively (P < 0.01). Of the noncured patients, 70% underwent additional surgery and none had postoperative lymph node metastasis.
CONCLUSIONS: Siewert type II adenocarcinoma encompasses two types of cancers with different etiologies: GCA and BEA. Although there are no significant differences in lifestyle-related background factors between GCA and BEA, BEA is a risk factor for noncurative resection via ESD.

Entities:  

Keywords:  Background factors; Barrett esophageal adenocarcinoma; Clinical outcomes of ESD; Esophagogastric junction adenocarcinoma; Gastric adenocarcinoma

Mesh:

Year:  2016        PMID: 27783167     DOI: 10.1007/s10120-016-0653-x

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  38 in total

1.  Two distinct pathways of tumorigenesis of adenocarcinomas of the esophagogastric junction, related or unrelated to intestinal metaplasia.

Authors:  Souya Nunobe; Yukihiro Nakanishi; Hirokazu Taniguchi; Mitsuru Sasako; Takeshi Sano; Hoichi Kato; Hisakazu Yamagishi; Shigeki Sekine; Tadakazu Shimoda
Journal:  Pathol Int       Date:  2007-06       Impact factor: 2.534

2.  Japanese gastric cancer treatment guidelines 2010 (ver. 3).

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

3.  Age-specific risk factor profiles of adenocarcinomas of the esophagus: A pooled analysis from the international BEACON consortium.

Authors:  Jennifer Drahos; Qian Xiao; Harvey A Risch; Neal D Freedman; Christian C Abnet; Lesley A Anderson; Leslie Bernstein; Linda Brown; Wong-Ho Chow; Marilie D Gammon; Farin Kamangar; Linda M Liao; Liam J Murray; Mary H Ward; Weimin Ye; Anna H Wu; Thomas L Vaughan; David C Whiteman; Michael B Cook
Journal:  Int J Cancer       Date:  2015-08-26       Impact factor: 7.396

Review 4.  Dietary salt intake and risk of gastric cancer.

Authors:  Lanfranco D'Elia; Ferruccio Galletti; Pasquale Strazzullo
Journal:  Cancer Treat Res       Date:  2014

Review 5.  A review of the epidemiology of Barrett's oesophagus and oesophageal adenocarcinoma.

Authors:  Jennifer L Schneider; Douglas A Corley
Journal:  Best Pract Res Clin Gastroenterol       Date:  2014-12-03       Impact factor: 3.043

Review 6.  Clinical outcomes of endoscopic submucosal dissection for early stage esophagogastric junction cancer: a systematic review and meta-analysis.

Authors:  Chan Hyuk Park; Eun Hye Kim; Ha Yan Kim; Yun Ho Roh; Yong Chan Lee
Journal:  Dig Liver Dis       Date:  2014-11-12       Impact factor: 4.088

7.  The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria.

Authors:  Prateek Sharma; John Dent; David Armstrong; Jacques J G H M Bergman; Liebwin Gossner; Yoshio Hoshihara; Janusz A Jankowski; Ola Junghard; Lars Lundell; Guido N J Tytgat; Michael Vieth
Journal:  Gastroenterology       Date:  2006-08-16       Impact factor: 22.682

8.  Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma.

Authors:  Hiroharu Yamashita; Hitoshi Katai; Shinji Morita; Makoto Saka; Hirokazu Taniguchi; Takeo Fukagawa
Journal:  Ann Surg       Date:  2011-08       Impact factor: 12.969

Review 9.  Review article: Barrett's oesophagus and carcinoma in Japan.

Authors:  M Hongo
Journal:  Aliment Pharmacol Ther       Date:  2004-12       Impact factor: 8.171

10.  Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion.

Authors:  Hendrik Manner; Oliver Pech; Yvonne Heldmann; Andrea May; Juergen Pohl; Angelika Behrens; Liebwin Gossner; Manfred Stolte; Michael Vieth; Christian Ell
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-26       Impact factor: 11.382

View more
  7 in total

Review 1.  Current surgical treatment of esophagogastric junction adenocarcinoma.

Authors:  Shun Zhang; Hajime Orita; Tetsu Fukunaga
Journal:  World J Gastrointest Oncol       Date:  2019-08-15

2.  Use of Immunostaining for the diagnosis of Lymphovascular invasion in superficial Barrett's esophageal adenocarcinoma.

Authors:  Isao Hosono; Ryoji Miyahara; Kazuhiro Furukawa; Kohei Funasaka; Tsunaki Sawada; Keiko Maeda; Takeshi Yamamura; Takuya Ishikawa; Eizaburo Ohno; Masanao Nakamura; Hiroki Kawashima; Takio Yokoi; Tetsuya Tsukamoto; Yoshiki Hirooka; Mitsuhiro Fujishiro
Journal:  BMC Gastroenterol       Date:  2020-06-05       Impact factor: 3.067

3.  Clinical outcomes of early gastric cardiac cancer treated with endoscopic submucosal dissection in patients with different indications.

Authors:  Ting Fan; Qi Sun; Shouli Cao; Xiangshan Fan; Qin Huang; Shu Zhang; Ying Lv; Xiaoqi Zhang; Tingsheng Ling; Lei Wang; Xiaoping Zou; Guifang Xu
Journal:  BMC Gastroenterol       Date:  2021-03-12       Impact factor: 3.067

4.  Endoscopic Submucosal Dissection for Superficial Barrett's Neoplasia in Korea: a Single-Center Experience.

Authors:  Dong Chan Joo; Gwang Ha Kim; Bong Eun Lee; Moon Won Lee; Dong Hoon Baek; Geun Am Song; Sojeong Lee; Do Youn Park
Journal:  J Gastric Cancer       Date:  2021-12-30       Impact factor: 3.720

5.  Clinicopathologic correlations of superficial esophageal adenocarcinoma in endoscopic submucosal dissection specimens.

Authors:  Sadhna Dhingra; Firas Bahdi; Sarah B May; Mohamed O Othman
Journal:  Diagn Pathol       Date:  2021-11-27       Impact factor: 2.644

6.  Endoscopic submucosal dissection for early esophagogastric junction adenocarcinomas: a systematic review.

Authors:  Paul Doumbe-Mandengue; Anna Pellat; Benoit Terris; Frédéric Beuvon; Mahaut Leconte; Anthony Dohan; Stanislas Chaussade; Romain Coriat; Maximilien Barret
Journal:  Ann Gastroenterol       Date:  2022-05-12

7.  Safety and long-term outcomes of early gastric cardiac cancer treated with endoscopic submucosal dissection in 499 Chinese patients.

Authors:  Shouli Cao; Tianhui Zou; Qi Sun; Tianyun Liu; Ting Fan; Qin Yin; Xiangshan Fan; Jingwei Jiang; Dekusaah Raymond; Yi Wang; Bin Zhang; Ying Lv; Xiaoqi Zhang; Tingsheng Ling; Yuzheng Zhuge; Lei Wang; Xiaoping Zou; Guifang Xu; Qin Huang
Journal:  Therap Adv Gastroenterol       Date:  2020-10-20       Impact factor: 4.409

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.